title: Reversible bronchial hyperresponsiveness induced by OK-T3/IL-2 administration in a patient with multiple myeloma.
abstract: Severe bronchial hyperresponsiveness to methacholine developed after intravenous therapy with OK-T3 and IL-2 in a patient with multiple myeloma, in whom no factors known to be associated with bronchial hyperresponsiveness were present. A substantial increase and activation of peripheral T-lymphocytes was observed after immunotherapy. Bronchial responsiveness and lymphocyte subsets both returned to normal baseline values 2 months after the patient was shifted to subcutaneous low dose administration of IL-2. The strict association between peripheral T-lymphocytes activation and the development of bronchial hyperresponsiveness suggests a causal relationship.
authors.affiliation: Department of Biomedical Science and Human Oncology, University of Torino, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Rolla
authors.forename: C
authors.initials: C
authors.lastname: Bucca
authors.forename: L
authors.initials: L
authors.lastname: Brussino
authors.forename: M
authors.initials: M
authors.lastname: Massaia
authors.forename: D
authors.initials: D
authors.lastname: Bergandi
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D016535:Bronchial Hyperreactivity / Q000209:etiology* / Q000473:pathology; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D007275:Injections, Intravenous; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D008213:Lymphocyte Activation; D016131:Lymphocyte Subsets / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000473:pathology / Q000628:therapy*; D013601:T-Lymphocytes / Q000502:physiology
chemical_list: D000911:Antibodies, Monoclonal; D007376:Interleukin-2